Inflammatory neuropathy is a group of conditions in which the immune system attacks the peripheral nerves, causing weakness, numbness, pain, or a combination of all three. The damage can be rapid, as in Guillain-Barré syndrome, or slow and relapsing, as in chronic inflammatory demyelinating polyneuropathy (CIDP). Because the immune system is involved rather than, say, diabetes or a toxin, these neuropathies respond to treatments that quiet or redirect the immune response. That distinction matters enormously for outcomes, but getting there requires recognizing the condition in the first place, which is harder than it sounds.
How the Immune System Damages Peripheral Nerves
In a healthy body, peripheral nerves are insulated by a fatty coating called myelin, which speeds electrical signals from the brain and spinal cord to muscles and sensory receptors. In most inflammatory neuropathies, the immune system mistakes components of myelin or the nerve fiber itself for a foreign invader and launches an attack. The result is demyelination: the myelin sheath breaks down, signals slow or stop, and the underlying nerve fiber (the axon) can be damaged as collateral.
The specific mechanism varies. In some cases, antibodies from the blood bind to proteins at the nodes of Ranvier, the tiny gaps between myelin segments where electrical impulses jump from one segment to the next. In roughly 30% of CIDP patients, antibodies have been found that target these nodal or paranodal regions.1PubMed Central. Pathology explains various mechanisms of auto-immune inflammatory peripheral neuropathies In other cases, immune cells called macrophages physically strip myelin from axons, though what directs them to do so remains unclear when no antibody target has been identified. When the attack hits the axon directly rather than the myelin, the damage tends to be harder to reverse. In one large biopsy study, nearly half of CIDP patients had already lost more than half of their normal nerve fiber density by the time they were diagnosed.2PubMed. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy
What Triggers the Attack
The causes split roughly into infections, autoimmune misfires, cancer-related immune reactions, and blood-vessel inflammation. Many cases have no single identifiable trigger, but the patterns researchers have uncovered are instructive.
Guillain-Barré syndrome, the best-known acute inflammatory neuropathy, is the clearest example of infection-triggered nerve damage. A preceding infection, often a gut or respiratory bug, prompts the immune system to produce antibodies against the pathogen. Unfortunately, certain sugar-fat molecules on the germ’s surface look almost identical to gangliosides concentrated in peripheral nerves. The antibodies bind to both, and the nerves get caught in the crossfire. At least five distinct bacterial and viral pathogens are known to trigger this “molecular mimicry.”3PubMed Central. Guillain-Barré syndrome: expanding the concept of molecular mimicry Campylobacter jejuni, a common cause of food poisoning, is the most frequently implicated.
In CIDP, the chronic counterpart of GBS, the trigger is murkier. Some patients develop the condition after an infection, but many do not. The immune attack smolders for months rather than flaring and resolving, suggesting a self-sustaining autoimmune loop. A subset of patients carry antibodies against specific paranodal proteins (contactin-1, neurofascin-155, and others), which has led to the newer label “autoimmune nodopathies” for these cases.1PubMed Central. Pathology explains various mechanisms of auto-immune inflammatory peripheral neuropathies
Cancer can also provoke inflammatory neuropathy. Paraneoplastic neuropathies arise when the immune system reacts to a tumor and, in the process, generates antibodies that cross-react with nerve tissue. Subacute sensory neuronopathy, which preferentially destroys the sensory nerve cell bodies in the dorsal root ganglia, is the most frequently observed peripheral paraneoplastic syndrome. Since 2004, the number of recognized antibodies and their associated tumors has expanded considerably.4PubMed Central. Paraneoplastic Neuropathies: What’s New Since the 2004 Recommended Diagnostic Criteria In a study of patients with paraneoplastic neuropathy and cancer-associated antibodies, most nerve biopsies showed reduced fiber density and swelling beneath the nerve’s protective sheath, and a subset had prominent inflammation around blood vessels consistent with a vasculitis-like process.5PubMed. Clinicopathologic Findings in Patients With Paraneoplastic Neuropathies and Antibodies Strongly Associated With Cancer
Vasculitic neuropathy represents yet another route. Here, inflammation targets the small blood vessels that supply the nerves themselves, cutting off oxygen. The result is an ischemic nerve injury. It can occur as part of a systemic vasculitis like polyarteritis nodosa, or it can be confined to the peripheral nerves alone, a condition called nonsystemic vasculitic neuropathy.6Brain. Nonsystemic vasculitic neuropathy Nerve biopsies in vasculitic neuropathy typically reveal axonal damage with active nerve fiber breakdown in the majority of cases and inflammatory cells clustered around blood vessels.7Frontiers in Neurology. Diagnostic Value of Sural Nerve Biopsy: Retrospective Analysis of Clinical Cases From 1981 to 2017
What Symptoms Look Like
The hallmark is progressive weakness and sensory loss in the limbs, but the specific pattern depends on which nerves are under attack and whether the damage is primarily demyelinating or axonal.
Demyelinating forms such as typical CIDP tend to cause symmetrical weakness that starts in both legs and progresses to the arms, along with reduced reflexes and a glove-and-stocking pattern of numbness or tingling. The weakness usually affects muscles closer to the trunk (thighs, upper arms) and farther out (hands, feet) alike. Some patients first notice they are tripping on curbs, struggling to open jars, or feeling unsteady on their feet. GBS follows a similar pattern but evolves over days to weeks rather than months, and in severe cases the weakness can climb to the muscles of breathing.
Pain deserves separate mention because it is frequently underappreciated. Neuropathic pain, caused by abnormal signaling in damaged nerve fibers, often affects the smallest sensory fibers first. Patients describe burning, electric-shock-like sensations, or a deep ache that conventional painkillers barely touch.8PubMed Central. Painful peripheral neuropathies In vasculitic and post-surgical inflammatory neuropathies, pain can be the very first symptom, presenting acutely and sometimes mimicking a mechanical injury like a compressed nerve.9Brain. Post-surgical inflammatory neuropathy
Multifocal motor neuropathy (MMN) breaks from the symmetrical pattern. It targets individual motor nerves asymmetrically, causing weakness in specific muscles, often in the forearms and hands, without significant sensory loss. MMN is driven by IgM antibodies against the ganglioside GM1, which are detectable in the large majority of patients when sensitive testing methods are used.10PubMed. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates A smaller fraction also carry antibodies against GM2, which appear to target Schwann cells (the cells that make myelin) and are associated with earlier disease onset.11PubMed Central. IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset
Autonomic Symptoms That Often Get Overlooked
The autonomic nervous system, which controls heart rate, blood pressure, sweating, and digestion, can also be affected by inflammatory neuropathy. In CIDP specifically, autonomic problems are more common than many clinicians expect. One study found that about half of CIDP patients had at least mild autonomic deficits on formal testing, most often involving sweating and heart-rate control, though the deficits were typically subtle.12PubMed Central. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy Another study using tilt-table testing found that roughly a quarter of CIDP patients met criteria for orthostatic hypotension (a drop in blood pressure upon standing) and about one in eight had postural tachycardia syndrome.13PubMed Central. The Prevalence and Severity of Autonomic Dysfunction in Chronic Inflammatory Demyelinating Polyneuropathy Symptoms like lightheadedness on standing, excessive or absent sweating, and bowel irregularity may be part of the neuropathy rather than unrelated problems.
How Inflammatory Neuropathy Is Diagnosed
Diagnosis rests on a combination of clinical examination, nerve conduction studies, spinal fluid analysis, and sometimes nerve biopsy. No single test is definitive, which is why misdiagnosis remains a real problem.
Nerve conduction studies are the workhorse. They measure how fast electrical signals travel along peripheral nerves and how much signal is lost along the way. In demyelinating neuropathies, signals are slowed, scattered in time (“temporal dispersion”), or partially blocked at specific points (“conduction block”). The 2021 European Academy of Neurology/Peripheral Nerve Society guidelines simplified the diagnostic framework for CIDP, collapsing three levels of certainty into two and reclassifying what used to be called “atypical CIDP” as “CIDP variants,” which include multifocal, focal, distal, motor, and sensory forms.14PubMed. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy Testing proximal nerve segments in the upper limbs can improve sensitivity, particularly when distal studies look borderline. Conduction block becomes highly specific at higher cutoff values at proximal sites.15PubMed. Proximal nerve conduction studies in chronic inflammatory demyelinating polyneuropathy
A lumbar puncture to check cerebrospinal fluid is often performed. Elevated protein with a normal cell count, called albuminocytological dissociation, is a classic finding in both GBS and CIDP. It is not specific to inflammatory neuropathy, though; it can show up in other conditions affecting the nervous system and even as a normal consequence of aging.16PubMed. Towards a standardised analysis of CSF in inflammatory neuropathies Younger patients sometimes show a discrepancy between total protein and more specific measures of blood-nerve barrier leakage, which can complicate interpretation.17Frontiers in Neurology. Comparative analysis of albumin quotient and total CSF protein in immune-mediated neuropathies
Nerve biopsy, usually of the sural nerve in the ankle, is reserved for cases where the diagnosis remains uncertain after other tests. It can reveal the characteristic onion-bulb formations of chronic demyelination and remyelination, inflammatory infiltrates, or vasculitis. In severe CIDP, the damage may look predominantly axonal rather than demyelinating, and electron microscopy can help distinguish it from a chronic idiopathic axonal neuropathy.18PubMed Central. Relevance of Nerve Biopsy in the Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy— A Systematic Review Patients with predominantly axonal pathology on biopsy tend to have worse disability and a poorer response to immune therapies.19Neurology India. Sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy
Nerve ultrasound is gaining traction as a non-invasive add-on. Scoring systems that quantify nerve enlargement patterns can help differentiate inflammatory neuropathies from hereditary ones, which sometimes look similar on nerve conduction studies.20PubMed. Ultrasound pattern sum score, homogeneity score and regional nerve enlargement index for differentiation of demyelinating inflammatory and hereditary neuropathies This is particularly useful because hereditary neuropathies like Charcot-Marie-Tooth disease and familial amyloid polyneuropathy can mimic CIDP, and mistaking one for the other has serious treatment implications.21PubMed. Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses
First-Line Treatments
Three established therapies form the backbone of treatment: intravenous immunoglobulin (IVIG), plasma exchange, and corticosteroids. Which is used depends on the specific condition, its severity, and how fast treatment is needed.
For GBS, IVIG and plasma exchange are the two main options. A meta-analysis comparing the two found no meaningful difference in the odds of achieving disability improvement, being functionally cured, requiring mechanical ventilation, or experiencing complications.22PubMed Central. Plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barré syndrome in patients with severe symptoms In practice, IVIG is often preferred because it is logistically simpler and patients are significantly less likely to discontinue treatment compared with plasma exchange. Corticosteroids, which are a staple in many autoimmune diseases, are not standard for GBS and can even worsen outcomes. However, when a patient labeled with GBS fails to improve on IVIG or plasma exchange but then responds dramatically to steroids, the true diagnosis may be a first episode of CIDP rather than GBS.23PubMed. Corticosteroids can help distinguish between Guillain-Barré syndrome and first attack of chronic inflammatory demyelinating neuropathy
For CIDP, all three options work. IVIG and corticosteroids are the most commonly used first-line agents, while plasma exchange is effective but harder to sustain long-term because of the need for repeated vascular access. Corticosteroids are inexpensive and widely available but carry well-known side effects with prolonged use. IVIG is well tolerated but costly. The choice often comes down to patient factors and local availability.24PubMed. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies
MMN is a notable exception. Plasma exchange is considered ineffective, and corticosteroids can actually make it worse. IVIG is the treatment of choice.24PubMed. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies Vasculitic neuropathy, by contrast, requires corticosteroids to control vessel inflammation and prevent further nerve ischemia, sometimes combined with other immunosuppressants.25PubMed. Primary and secondary vasculitic neuropathy
Long-Term Maintenance and Subcutaneous Immunoglobulin
CIDP often requires ongoing treatment. Many patients relapse when IVIG is tapered. This is where subcutaneous immunoglobulin (SCIg) has become an important option. Rather than sitting for hours in an infusion center every few weeks, patients can self-administer smaller, more frequent doses at home via a small needle under the skin. The PATH trial, the largest CIDP trial to date, demonstrated that SCIg at two different weekly doses prevented relapse and was well tolerated.26PubMed. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH) Long-term extension data showed sustained benefit at both dose levels, with fewer relapses on the higher dose, and the importance of tailoring the dose to the individual patient.27PubMed Central. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study Separate data have followed patients on SCIg for up to seven years with continued stabilization and, in some cases, functional improvement.28PubMed Central. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
Emerging Therapies
The treatment pipeline is expanding beyond immunoglobulin and steroids. Complement inhibitors, which block a specific arm of the immune cascade implicated in nerve damage, are under active investigation. Eculizumab, already approved for other autoimmune conditions, is being studied in GBS. A C1q inhibitor (ANX005) is also in trials for GBS, and a C1s inhibitor (SAR445088) is being tested in CIDP.29PubMed Central. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies Another approach targets FcRn, the receptor that recycles IgG antibodies and keeps their levels high in the blood. Efgartigimod, an FcRn blocker delivered subcutaneously, is being investigated in CIDP with the rationale that lowering pathogenic antibody levels could reduce nerve damage without the broad immunosuppression of steroids.30PubMed. Novel therapies in CIDP None of these are approved for inflammatory neuropathy yet, but they represent a shift toward more targeted treatments.
Exercise and Rehabilitation
Immune therapy addresses the underlying attack, but it does not automatically restore the strength and balance that were lost. Structured exercise programs fill that gap. A systematic review of exercise in GBS and CIDP found that programs combining resistance training, aerobic activity, balance work, and breathing exercises were associated with improvements in fatigue and physical function. The best outcomes appeared in supervised, individually designed sessions lasting 45 to 60 minutes, three to four times a week for at least 12 weeks.31PubMed. Impact of Physical Exercise Programs on Fatigue and Functional Capacity in People With Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy
Even unsupervised community-based programs produce measurable gains. In one prospective study, people with stable motor neuropathy who followed a 12-week home exercise program saw significant improvements in activity limitation, anxiety, depression, and fatigue. Most of those improvements held at six months after the program ended.32PubMed. A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy Balance-focused programs, such as the Otago exercise program, have shown improvements in walking speed and stability in CIDP patients, with most participants retaining the benefits at three months post-intervention.33Physiotherapy Practice and Research: The Official Journal of The Irish Society of Chartered Physiotherapists. A clinical case series investigating the effectiveness of an exercise intervention in chronic inflammatory demyelinating polyneuropathy The key point is that exercise is safe and genuinely helpful in stable disease; the old advice to rest and avoid exertion has been largely replaced by encouragement to move.
Inflammatory Neuropathy in Children
Pediatric inflammatory neuropathy is rarer than the adult form but follows broadly similar principles. In a multicenter study of 43 children with CIDP, about half were male and half female, and first-line treatment consisted of IVIG alone or combined with steroids in over 90% of cases. Disability scores improved significantly with treatment across the group.34PubMed. Pediatric-Onset Chronic Inflammatory Demyelinating Polyneuropathy: A Multicenter Study Outcomes were generally favorable, though residual neurological deficits were common and some children required escalation to immunosuppressive agents like azathioprine or rituximab. A smaller case series found that disease severity ranged from a single episode to progressive disease resistant to multiple therapies, but most children reached a relatively favorable functional status.35PubMed Central. Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions Children with abnormal MRI findings at diagnosis tended to have higher disability at the outset, which may help identify those who need more aggressive early treatment.
How Common Is It, and Who Is at Risk
CIDP, the most studied chronic form, is uncommon but not vanishingly rare. A meta-analysis pooling data from multiple countries estimated a prevalence of about 2.8 per 100,000 people, with an incidence of about 0.33 new cases per 100,000 per year.36PubMed Central. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis Rates vary considerably depending on the diagnostic criteria used and the population studied. A Dutch study found a notably higher prevalence of 7 per 100,000, with men affected about three times as often as women and people over 50 at dramatically higher risk than younger adults.37PubMed Central. Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands Data from Chile reported prevalence and incidence figures in a similar range, and about a fifth of patients in that cohort also had diabetes, a condition that can both coexist with and complicate the diagnosis of CIDP.38PubMed. Epidemiology of chronic inflammatory demyelinating polyneuropathy in the South-Eastern area of Santiago, Chile GBS is somewhat more common in incidence, typically estimated at one to two cases per 100,000 annually, but because most patients recover, its prevalence at any given time is lower.
The Financial and Personal Toll
Inflammatory neuropathies, particularly CIDP requiring ongoing immunoglobulin, carry a substantial economic burden. A systematic review of burden-of-illness studies found annual costs per patient ranging from roughly £22,000 in the UK to about €47,000 in France, with two-year costs in the US exceeding $116,000. Drug costs, primarily immunoglobulin, were the dominant driver of direct medical spending.39PubMed Central. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP) Beyond the bills, patients face real quality-of-life consequences. Roughly one in ten CIDP patients meets criteria for depression, and premature retirement due to the disease affects an estimated 14 to 28% of patients. Among those who retired early, the odds of depression and fatigue were many times higher than among those who continued working. Fatigue is often described by patients as the single most disabling symptom, even when strength is relatively preserved, and it is one of the clearest areas where structured exercise has been shown to help.
Diagnostic Boundaries That Are Still Shifting
The edges of inflammatory neuropathy remain genuinely uncertain. Recent research has highlighted three persistent zones of diagnostic confusion: the limits of nerve conduction criteria (some real CIDP cases do not meet the standard electrical thresholds), the borderline between CIDP and neuropathy caused by anti-MAG antibodies (a related but distinct condition driven by IgM antibodies against a specific myelin protein), and the question of whether purely axonal variants of CIDP exist and how to identify them.40PubMed Central. Controversies in the diagnosis of chronic inflammatory demyelinating polyneuropathy Blood-based biomarkers such as neurofilament light chain, a protein released when axons are injured, are being investigated as tools to detect disease activity without relying solely on electrical studies. For now, though, diagnosis still depends on a clinician who knows what to look for and is willing to pursue the workup even when initial tests are equivocal. The stakes of getting it right are high: a treatable inflammatory neuropathy mistaken for a degenerative condition means a patient misses out on therapies that can meaningfully change their life.